Suppr超能文献

相似文献

1
mTORC1 promotes survival through translational control of Mcl-1.
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10853-8. doi: 10.1073/pnas.0804821105. Epub 2008 Jul 29.
7
Tumorigenic activity and therapeutic inhibition of Rheb GTPase.
Genes Dev. 2008 Aug 15;22(16):2178-88. doi: 10.1101/gad.1690808.
9
Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas.
Clin Cancer Res. 2009 Mar 15;15(6):1940-6. doi: 10.1158/1078-0432.CCR-08-2364. Epub 2009 Mar 10.
10
The TSC1-TSC2 complex is required for proper activation of mTOR complex 2.
Mol Cell Biol. 2008 Jun;28(12):4104-15. doi: 10.1128/MCB.00289-08. Epub 2008 Apr 14.

引用本文的文献

2
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers.
Nat Commun. 2025 May 2;16(1):4112. doi: 10.1038/s41467-025-58753-y.
5
PHGDH inhibition and FOXO3 modulation drives PUMA-dependent apoptosis in osteosarcoma.
Cell Death Dis. 2025 Feb 12;16(1):89. doi: 10.1038/s41419-025-07378-6.
6
AKT kinases as therapeutic targets.
J Exp Clin Cancer Res. 2024 Nov 29;43(1):313. doi: 10.1186/s13046-024-03207-4.
7
Small molecule Mcl-1 inhibitor for triple negative breast cancer therapy.
Front Cell Dev Biol. 2024 Sep 20;12:1408107. doi: 10.3389/fcell.2024.1408107. eCollection 2024.
8
Combined inhibition of KRAS and mTORC1 kinase is synergistic in non-small cell lung cancer.
Nat Commun. 2024 Jul 19;15(1):6076. doi: 10.1038/s41467-024-50063-z.
9
Passenger Gene Coamplifications Create Collateral Therapeutic Vulnerabilities in Cancer.
Cancer Discov. 2024 Mar 1;14(3):492-507. doi: 10.1158/2159-8290.CD-23-1189.
10
HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B.
Cell Rep Med. 2023 Nov 21;4(11):101285. doi: 10.1016/j.xcrm.2023.101285. Epub 2023 Nov 10.

本文引用的文献

1
Targeting the eukaryotic translation initiation factor 4E for cancer therapy.
Cancer Res. 2008 Feb 1;68(3):631-4. doi: 10.1158/0008-5472.CAN-07-5635.
2
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.
Drug Resist Updat. 2008 Feb-Apr;11(1-2):32-50. doi: 10.1016/j.drup.2007.11.003. Epub 2007 Dec 31.
3
Dissecting eIF4E action in tumorigenesis.
Genes Dev. 2007 Dec 15;21(24):3232-7. doi: 10.1101/gad.1604407. Epub 2007 Nov 30.
4
A pivotal role for Mcl-1 in Bortezomib-induced apoptosis.
Oncogene. 2008 Jan 31;27(6):721-31. doi: 10.1038/sj.onc.1210679. Epub 2007 Jul 23.
5
Defining the role of mTOR in cancer.
Cancer Cell. 2007 Jul;12(1):9-22. doi: 10.1016/j.ccr.2007.05.008.
7
S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth.
Science. 2006 Oct 20;314(5798):467-71. doi: 10.1126/science.1130276.
9
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.
Cancer Cell. 2006 Oct;10(4):331-42. doi: 10.1016/j.ccr.2006.09.006. Epub 2006 Sep 28.
10
Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo.
Cancer Res. 2006 Aug 1;66(15):7639-46. doi: 10.1158/0008-5472.CAN-06-0419.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验